C4 Therapeutics (NASDAQ:CCCC) Given Overweight Rating at Stephens

Stephens reaffirmed their overweight rating on shares of C4 Therapeutics (NASDAQ:CCCC) in a research report released on Monday,Benzinga reports. They currently have a $6.00 price target on the stock.

A number of other brokerages have also issued reports on CCCC. Barclays boosted their target price on shares of C4 Therapeutics from $8.00 to $10.00 and gave the company an “overweight” rating in a research note on Monday. Wall Street Zen lowered shares of C4 Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Zacks Research lowered shares of C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 22nd. Finally, Guggenheim initiated coverage on shares of C4 Therapeutics in a research note on Wednesday, September 3rd. They set a “buy” rating and a $8.00 target price for the company. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

C4 Therapeutics Stock Down 6.6%

NASDAQ CCCC opened at $2.42 on Monday. The firm has a market capitalization of $172.23 million, a price-to-earnings ratio of -1.53 and a beta of 2.98. C4 Therapeutics has a 52 week low of $1.09 and a 52 week high of $7.14. The company has a fifty day moving average of $2.54 and a two-hundred day moving average of $1.92.

C4 Therapeutics (NASDAQ:CCCC) last issued its earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.01. The firm had revenue of $6.46 million during the quarter, compared to analyst estimates of $5.24 million. C4 Therapeutics had a negative net margin of 325.88% and a negative return on equity of 53.91%. Equities research analysts anticipate that C4 Therapeutics will post -1.52 EPS for the current year.

Institutional Trading of C4 Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. bought a new stake in shares of C4 Therapeutics in the first quarter valued at about $1,116,000. Jane Street Group LLC raised its holdings in shares of C4 Therapeutics by 49.4% in the fourth quarter. Jane Street Group LLC now owns 152,774 shares of the company’s stock valued at $550,000 after acquiring an additional 50,523 shares in the last quarter. Millennium Management LLC raised its holdings in shares of C4 Therapeutics by 1,548.3% in the fourth quarter. Millennium Management LLC now owns 360,125 shares of the company’s stock valued at $1,296,000 after acquiring an additional 338,277 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of C4 Therapeutics in the first quarter valued at about $680,000. Finally, Nuveen Asset Management LLC raised its holdings in shares of C4 Therapeutics by 6.4% in the fourth quarter. Nuveen Asset Management LLC now owns 192,424 shares of the company’s stock valued at $693,000 after acquiring an additional 11,571 shares in the last quarter. 78.81% of the stock is currently owned by institutional investors.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.